Mutch Elaine, Nave Ruediger, McCracken Nigel, Zech Karl, Williams Faith M
Toxicology Unit, Clinical and Laboratory Sciences, The University of Newcastle, Newcastle upon Tyne, UK.
Biochem Pharmacol. 2007 May 15;73(10):1657-64. doi: 10.1016/j.bcp.2007.01.031. Epub 2007 Jan 28.
Ciclesonide (CIC) is an inhaled glucocorticosteroid. This study aimed to identify esterases involved in the metabolism of CIC to the active metabolite desisobutyryl-ciclesonide (des-CIC), and to measure hydrolysis rates in human liver, lung and plasma and normal human bronchial epithelial (NHBE) cells in vitro. Ciclesonide (5 microM and 500 microM) was incubated with microsomal or cytosolic fractions from liver, lung and plasma (n=4 for each) and des-CIC formation was determined by reverse-phase high-performance liquid chromatography with U.V. detection. The roles of carboxylesterase, cholinesterase and A-esterase in CIC hydrolysis were determined using a range of inhibitors. Inhibitor concentrations for liver and NHBE cells were 100 microM and 5 microM, respectively. Liver tissue had a higher activity for 500 microM CIC hydrolysis (microsomes: 25.4; cytosol: 62.9 nmol/g tissue/min) than peripheral lung (microsomes: 0.089; cytosol: 0.915 nmol/g tissue/min) or plasma (0.001 nmol/mL plasma/min), corresponding with high levels of carboxylesterase and cholinesterase in the liver compared with the lung. CIC (5 microM) was rapidly hydrolyzed by NHBE cells (approximately 30% conversion at 4h), with almost complete conversion by 24h. In liver and NHBE cells, major involvement of cytosolic carboxylesterases, with some contribution by cholinesterases, was indicated. The highest level of conversion was found in the liver, the site of inactivation of des-CIC through rapid oxidation by cytochrome P450. Carboxylesterases in bronchial epithelial cells probably contribute significantly to the conversion to des-CIC in the target organ, whereas low systemic levels of des-CIC are a result of the high metabolic clearance by the liver following CIC inhalation.
环索奈德(CIC)是一种吸入性糖皮质激素。本研究旨在确定参与CIC代谢生成活性代谢物去异丁酰基环索奈德(去CIC)的酯酶,并在体外测量人肝脏、肺组织、血浆及正常人支气管上皮(NHBE)细胞中的水解速率。将环索奈德(5微摩尔/升和500微摩尔/升)与来自肝脏、肺组织和血浆的微粒体或胞质部分一起孵育(每组n = 4),并通过反相高效液相色谱法和紫外检测来测定去CIC的生成。使用一系列抑制剂来确定羧酸酯酶、胆碱酯酶和A酯酶在CIC水解中的作用。肝脏和NHBE细胞的抑制剂浓度分别为100微摩尔/升和5微摩尔/升。肝脏组织对500微摩尔/升CIC水解的活性(微粒体:25.4;胞质:62.9纳摩尔/克组织/分钟)高于外周肺(微粒体:0.089;胞质:0.915纳摩尔/克组织/分钟)或血浆(0.001纳摩尔/毫升血浆/分钟),这与肝脏中羧酸酯酶和胆碱酯酶的水平高于肺组织相对应。NHBE细胞能迅速水解CIC(5微摩尔/升)(4小时时转化率约为30%),到24小时时几乎完全转化。在肝脏和NHBE细胞中,表明主要是胞质羧酸酯酶起作用,胆碱酯酶也有一定贡献。转化率最高的是肝脏,去CIC在肝脏中通过细胞色素P450快速氧化而失活。支气管上皮细胞中的羧酸酯酶可能对靶器官中CIC转化为去CIC有显著贡献,而吸入CIC后肝脏的高代谢清除导致去CIC的全身水平较低。